Literature DB >> 19293773

Host and vector-dependent effects on the risk of germline transmission of AAV vectors.

Patricia Favaro1, Harre D Downey, J Shangzhen Zhou, J Fraser Wright, Bernd Hauck, Federico Mingozzi, Katherine A High, Valder R Arruda.   

Abstract

The assessment of the risk of germline transmission of vector-coded sequences is critical for clinical translation of gene transfer strategies. We used rabbit models to analyze the risk of germline transmission of adeno-associated viral (AAV) vectors. Intravenous injection of AAV-2 or AAV-8 resulted in liver-mediated, long-term expression of therapeutic levels of human factor IX (hFIX) in a dose-dependent manner. In high-dose cohorts, AAV-8 resulted in twofold higher levels of circulating hFIX and of vector DNA in liver compared to AAV-2. Vector sequences were found in the semen of all rabbits. The kinetics of vector clearance from semen was dose- and time-dependent but serotype-independent. No late recurrence of AAV-8 sequences was found in the semen over several consecutive cycles of spermatogenesis. In a novel rabbit model, AAV-2 or AAV-8 sequences were detected in the semen of vasectomized animals that lack germ cells. Therefore, structures of the genitourinary (GU) tract, as well as the testis, contribute significantly to vector shedding in the semen. Collectively, data from these two models suggest that the risk of inadvertent germline transmission in males by AAV-8 vectors is low, similar to that of AAV-2, and that AAV dissemination to the semen is in part modulated by host-dependent factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293773      PMCID: PMC2835193          DOI: 10.1038/mt.2009.56

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

1.  Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Authors:  M Moskalenko; L Chen; M van Roey; B A Donahue; R O Snyder; J G McArthur; S D Patel
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.

Authors:  V R Arruda; P A Fields; R Milner; L Wainwright; M P De Miguel; P J Donovan; R W Herzog; T C Nichols; J A Biegel; M Razavi; M Dake; D Huff; A W Flake; L Couto; M A Kay; K A High
Journal:  Mol Ther       Date:  2001-12       Impact factor: 11.454

3.  Generation and characterization of chimeric recombinant AAV vectors.

Authors:  Bernd Hauck; Ling Chen; Weidong Xiao
Journal:  Mol Ther       Date:  2003-03       Impact factor: 11.454

4.  Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.

Authors:  Amit C Nathwani; Andrew M Davidoff; Hideki Hanawa; Yunyu Hu; Fredric A Hoffer; Alexander Nikanorov; Clive Slaughter; Catherine Y C Ng; Junfang Zhou; Jay N Lozier; Timothy D Mandrell; Elio F Vanin; Arthur W Nienhuis
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

5.  Quantification of adeno-associated virus particles and empty capsids by optical density measurement.

Authors:  Jürg M Sommer; Peter H Smith; Sumathy Parthasarathy; Jesse Isaacs; Sharmila Vijay; Jane Kieran; Sharon K Powell; Alan McClelland; J Fraser Wright
Journal:  Mol Ther       Date:  2003-01       Impact factor: 11.454

6.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

8.  Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

Authors:  Jerry S Powell; Margaret V Ragni; Gilbert C White; Jeanne M Lusher; Carol Hillman-Wiseman; Tom E Moon; Veronica Cole; Sandhya Ramanathan-Girish; Holger Roehl; Nancy Sajjadi; Douglas J Jolly; Deborah Hurst
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

9.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

10.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

View more
  15 in total

1.  Gene-based passive antibody protection from HIV.

Authors:  Margaret A Liu
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

Review 2.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

3.  Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model.

Authors:  Patricia Favaro; Jonathan D Finn; Joshua I Siner; J Fraser Wright; Katherine A High; Valder R Arruda
Journal:  Hum Gene Ther       Date:  2011-03-08       Impact factor: 5.695

Review 4.  The gene therapy journey for hemophilia: are we there yet?

Authors:  Katherine A High
Journal:  Blood       Date:  2012-07-24       Impact factor: 22.113

5.  Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response.

Authors:  Kathrina Quinn; Mary R Quirion; Chia-Yun Lo; Julia A Misplon; Suzanne L Epstein; John A Chiorini
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

6.  Sustained normalization of neurological disease after intracranial gene therapy in a feline model.

Authors:  Victoria J McCurdy; Aime K Johnson; Heather L Gray-Edwards; Ashley N Randle; Brandon L Brunson; Nancy E Morrison; Nouha Salibi; Jacob A Johnson; Misako Hwang; Ronald J Beyers; Stanley G Leroy; Stacy Maitland; Thomas S Denney; Nancy R Cox; Henry J Baker; Miguel Sena-Esteves; Douglas R Martin
Journal:  Sci Transl Med       Date:  2014-04-09       Impact factor: 17.956

7.  Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia.

Authors:  Shu-Jen Chen; Julio Sanmiguel; Martin Lock; Deirdre McMenamin; Christine Draper; Maria P Limberis; Sadik H Kassim; Suryanarayan Somanathan; Peter Bell; Julie C Johnston; Daniel J Rader; James M Wilson
Journal:  Hum Gene Ther Clin Dev       Date:  2013-11-09       Impact factor: 5.032

8.  Endogenous viral elements in animal genomes.

Authors:  Aris Katzourakis; Robert J Gifford
Journal:  PLoS Genet       Date:  2010-11-18       Impact factor: 5.917

9.  Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.

Authors:  David M Markusic; Roland W Herzog
Journal:  J Genet Syndr Gene Ther       Date:  2012-01-18

10.  Obstacles and future of gene therapy for hemophilia.

Authors:  Valder R Arruda; Ben J Samelson-Jones
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-18       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.